Technical Analysis for BWAY - Brainsway Ltd.

Grade Last Price % Change Price Change
D 5.29 0.76% 0.04
BWAY closed up 0.76 percent on Thursday, March 28, 2024, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.76%
Below Lower BB Weakness 0.76%
Lower Bollinger Band Touch Weakness 0.76%
Oversold Stochastic Weakness 0.76%
Lower Bollinger Band Walk Weakness -2.94%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
Possible Inside Day about 15 hours ago
Rose Above Lower Bollinger Band about 19 hours ago
2x Volume Pace about 19 hours ago
1.5x Volume Pace about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience FDA Mental Health Opioids Stroke Major Depressive Disorder Multiple Sclerosis Psychiatry Neurophysiology Neuromodulation Depressive Disorder Neurotechnology Smoking Neuropsychology Post Traumatic Stress Disorder Treatment Of Major Depressive Disorder Smoking Cessation Obsessive Compulsive Disorder Addiction Neuromodulation Products Treatment Of Depression Non Invasive Neuromodulation Products Transcranial Magnetic Stimulation

Is BWAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.615
52 Week Low 1.38
Average Volume 125,894
200-Day Moving Average 4.54
50-Day Moving Average 6.10
20-Day Moving Average 5.91
10-Day Moving Average 5.69
Average True Range 0.36
RSI (14) 35.48
ADX 11.18
+DI 16.81
-DI 26.65
Chandelier Exit (Long, 3 ATRs) 5.73
Chandelier Exit (Short, 3 ATRs) 6.31
Upper Bollinger Bands 6.59
Lower Bollinger Band 5.23
Percent B (%b) 0.04
BandWidth 23.00
MACD Line -0.22
MACD Signal Line -0.15
MACD Histogram -0.0765
Fundamentals Value
Market Cap 87.93 Million
Num Shares 16.6 Million
EPS -0.48
Price-to-Earnings (P/E) Ratio -11.02
Price-to-Sales 3.45
Price-to-Book 2.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.54
Resistance 3 (R3) 5.55 5.48 5.50
Resistance 2 (R2) 5.48 5.41 5.47 5.48
Resistance 1 (R1) 5.38 5.37 5.43 5.37 5.47
Pivot Point 5.31 5.31 5.34 5.31 5.31
Support 1 (S1) 5.22 5.25 5.27 5.21 5.11
Support 2 (S2) 5.15 5.21 5.14 5.10
Support 3 (S3) 5.05 5.15 5.08
Support 4 (S4) 5.04